Open AccessCyclooxygenases 1 and 2 Differentially Regulate Blood Pressure and Cerebrovascular Responses to Acute and Chronic Intermittent Hypoxia: Implications for Sleep Apnea
Author(s) -
Beaudin Andrew E.,
Pun Matiram,
Yang Christina,
Nicholl David D. M.,
Steinback Craig D.,
Slater Donna M.,
WynneEdwards Katherine E.,
Hanly Patrick J.,
Ahmed Sofia B.,
Poulin Marc J.
Publication year - 2014
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.114.000875
Subject(s) - medicine , intermittent hypoxia , blood pressure , cyclooxygenase , prostanoid , obstructive sleep apnea , cerebral blood flow , hypoxia (environmental) , sleep apnea , urinary system , crossover study , endocrinology , prostaglandin , anesthesia , placebo , pathology , biochemistry , chemistry , organic chemistry , oxygen , enzyme , alternative medicine
Background Obstructive sleep apnea ( OSA ) is associated with increased risk of cardiovascular and cerebrovascular disease resulting from intermittent hypoxia ( IH )‐induced inflammation. Cyclooxygenase ( COX )‐formed prostanoids mediate the inflammatory response, and regulate blood pressure and cerebral blood flow ( CBF ), but their role in blood pressure and CBF responses to IH is unknown. Therefore, this study's objective was to determine the role of prostanoids in cardiovascular and cerebrovascular responses to IH . Methods and Results Twelve healthy, male participants underwent three, 6‐hour IH exposures. For 4 days before each IH exposure, participants ingested a placebo, indomethacin (nonselective COX inhibitor), or Celebrex ® (selective COX ‐2 inhibitor) in a double‐blind, randomized, crossover study design. Pre‐ and post‐ IH blood pressure, CBF , and urinary prostanoids were assessed. Additionally, blood pressure and urinary prostanoids were assessed in newly diagnosed, untreated OSA patients (n=33). Nonselective COX inhibition increased pre‐ IH blood pressure ( P ≤0.04) and decreased pre‐ IH CBF ( P =0.04) while neither physiological variable was affected by COX ‐2 inhibition ( P ≥0.90). Post‐ IH , MAP was elevated ( P ≤0.05) and CBF was unchanged with placebo and nonselective COX inhibition. Selective COX ‐2 inhibition abrogated the IH ‐induced MAP increase ( P =0.19), but resulted in lower post‐ IH CBF ( P =0.01). Prostanoids were unaffected by IH , except prostaglandin E 2 was elevated with the placebo ( P =0.02). Finally, OSA patients had elevated blood pressure ( P ≤0.4) and COX ‐1 formed thromboxane A 2 concentrations ( P =0.02). Conclusions COX ‐2 and COX ‐1 have divergent roles in modulating vascular responses to acute and chronic IH . Moreover, COX ‐1 inhibition may mitigate cardiovascular and cerebrovascular morbidity in OSA . Clinical Trial Registration URL: www.clinicaltrials.gov . Unique identifier: NCT01280006